Research Keyword: drug resistance

Primary cutaneous mixed infection with Cryptococcus uniguttulatus and Mycobacterium tuberculosis

mycolabadmin

A 43-year-old man had a persistent facial rash that didn’t improve with standard antifungal treatments. Doctors initially found a fungal infection called Cryptococcus uniguttulatus using culture tests. However, advanced molecular testing (DNA sequencing) revealed he also had a tuberculosis infection in the same skin lesion. Once both infections were treated with appropriate medications, the patient’s rash finally improved. This case shows that sometimes people can have multiple infections at the same location and that newer diagnostic methods are important for finding these hidden infections.

Read More »

Genome-Mining Based Discovery of Pyrrolomycin K and L from the Termite-Associated Micromonospora sp. RB23

mycolabadmin

Researchers discovered two new antimicrobial compounds called pyrrolomycins from a bacterium found in termite guts using genome analysis and advanced chemistry techniques. These compounds are modified versions of known antimicrobial molecules, featuring halogenated structures. Interestingly, the bacteria appears to protect itself from its own toxic compounds through chemical modifications, a strategy that researchers believe could inform the design of new antibiotics to combat drug-resistant bacteria.

Read More »

Antifungal potential of copper oxide nanoparticles against Microsporum canis isolates in canine and feline dermatophytosis

mycolabadmin

Researchers tested tiny copper oxide particles created using plant extracts against a fungus that causes ringworm in dogs and cats. These nanoparticles successfully killed the fungus in laboratory tests, with effectiveness at concentrations ranging from 500-2,000 parts per million. While slightly less effective than current medications, the nanoparticles showed promise as an alternative treatment, especially important as the fungus becomes resistant to traditional drugs.

Read More »

The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release

mycolabadmin

Researchers discovered that a small peptide derived from a bacterium called EntV can fight Candida fungal infections by targeting specialized vesicles (tiny sacs) that fungi use to spread infections. Unlike traditional antifungal drugs that kill fungi, EntV works by blocking the release of these vesicles, reducing the fungus’s ability to infect and form protective biofilms. This new approach could lead to treatments that work against drug-resistant fungi without the toxicity issues of current antifungals.

Read More »

Harnessing Natural Products to Surmount Drug Resistance in Gastric Cancer: Mechanisms and Therapeutic Perspectives

mycolabadmin

Gastric cancer is a serious disease that often becomes resistant to chemotherapy drugs, making treatment difficult. This review examines how natural products found in plants and herbs can help overcome this drug resistance. These natural compounds work through multiple mechanisms, including targeting cancer stem cells, boosting the immune system, and enhancing the effectiveness of standard chemotherapy treatments.

Read More »

The Ptk2-Pma1 pathway enhances tolerance to terbinafine in Trichophyton rubrum

mycolabadmin

Researchers discovered that a protein called TrPtk2 helps dermatophytes resist terbinafine, a common antifungal medicine. They found that blocking this protein makes the fungus more susceptible to terbinafine. Additionally, they discovered that omeprazole, a stomach medication approved for human use, can be combined with terbinafine to make it more effective against resistant fungal infections.

Read More »
Scroll to Top